【the yellowstone clayton homes】Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE,the yellowstone clayton homes Mass., Dec. 31, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on December 31, 2021 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 25 individuals hired by Sarepta in December 2021. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
The employees received, in the aggregate, options to purchase 19,175 shares of Sarepta's common stock, and in the aggregate 9,900 restricted stock units (“RSUs”). The options have an exercise price of $90.05 per share, which is equal to the closing price of Sarepta's common stock on December 31, 2021 (the “Grant Date”). One-fourth of the shares underlying each employee’s option will vest on the one-year anniversary of the Grant Date and thereafter 1/48th of the shares underlying each employee’s option will vest monthly, such that the shares underlying the option granted to each employee will be fully vested on the fourth anniversary of the Grant Date, in each case, subject to each such employee’s continued employment with Sarepta on such vesting dates.
One-fourth of the RSUs will vest yearly on each anniversary of the Grant Date, such that the RSUs granted to each employee will be fully vested on the fourth anniversary of the Grant Date, in each case, subject to each such employee’s continued employment with Sarepta on such vesting date.
About Sarepta Therapeutics
Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 programs in various stages of development. Our vast pipeline is driven by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing. For more information, please visit
www.sarepta.com
or follow us on
,
,
and
.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at
www.sarepta.com
. We encourage investors and potential investors to consult our website regularly for important information about us.
Source: Sarepta Therapeutics, Inc.
Investor Contact:
Ian Estepan, 617-274-4052
Media Contact:
Tracy Sorrentino, 617-301-8566
Story continues
View comments
(责任编辑:Focus)
- ·Technical Enzymes Market 2028 - Global Insights on Trends, Regulatory Landscape, Value Chain Analysis, Key Stakeholders, Growth Drivers and Future Outlook: Adroit Market Research
- ·BRIEF- Longino & Cardenal Prelim. FY Revenue Up 12.2 pct YoY
- ·Apple's iPhone sales leave investors feeling sour as they wait to hear from the Fed
- ·BRIEF-Songz Automobile Air Conditioning Signs Agreement To Receive Land Compensation
- ·Bitcoin Sees Record Number of Active Users as Price Almost Hits $20K
- ·PayPoint plc : Total voting rights
- ·Excerpts of high court campaign finance opinions
- ·Should You Be Worried About Vista Group International Limited’s (NZSE:VGL) 8.0% Return On Equity?
- ·Role of Wireless ICT in Healthcare Markets, 2020 Report - Focus on WICT and M2M Communications, Self-powered Wireless Sensors, Underlying Technologies, & WBAN/WMBAN Features and Standardization
- ·Brinker International Enters Oversold Territory
- ·One Spark Networks SE (NYSEMKT:LOV) Broker Analyst Just Cut Their Revenue Numbers By 15%
- ·Survey Says: Watch Out for Attorneys With Their Lies, Expletives and Nasty Email
- ·Man Wah Holdings Limited (HKG:1999): Did It Outperform The Industry?
- ·New mechanism for European trade with Iran is legitimate - Germany's BGA
- ·Calculating The Fair Value Of Motorola Solutions, Inc. (NYSE:MSI)
- ·Navigant Consulting Inc (NCI) Files 10-K for the Fiscal Year Ended on December 31, 2018
- ·Trump to meet China's Xi to try to seal trade deal, progress reported
- ·Why Mangalore Refinery and Petrochemicals Limited (NSE:MRPL) Could Be Your Next Investment
- ·Snapchat Ousts Trump’s Account From Discover Section
- ·3 things small business owners should know for 2019